Intraventricular immune checkpoint inhibition with nivolumab in relapsed primary central nervous system lymphoma

Neurooncol Adv. 2022 Apr 13;4(1):vdac051. doi: 10.1093/noajnl/vdac051. eCollection 2022 Jan-Dec.

Leon D Kaulen^{1

2}, Christoph Gumbinger¹, Felix Hinz^{3

4}, Tobias Kessler^{1

2}, Frank Winkler^{1

2}, Martin Bendszus⁵, Felix Sahm^{3

4}, Wolfgang Wick^{1

2}

¹ Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.
² Clinical Cooperation Unit Neuro-Oncology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
³ Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany.
⁴ Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
⁵ Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.

No abstract available